Polaris Capital Management’s Pacira BioSciences PCRX Stock Holding History

Polaris Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-5,600	Closed	-$160K	–	94
2024 Q2	$160K	Hold	5,600	–	–	0.01%	91
2024 Q1	$164K	Sell	5,600 -16,400	-75%	-$504K	0.01%	91
2023 Q4	$742K	Sell	22,000 -3,300	-13%	-$96.5K	0.04%	89
2023 Q3	$776K	Hold	25,300	–	–	0.04%	83
2023 Q2	$1.01M	Hold	25,300	–	–	0.04%	80
2023 Q1	$1.03M	Hold	25,300	–	–	0.04%	78
2022 Q4	$977K	Buy	25,300 +13,400	+113%	+$652K	0.03%	81
2022 Q3	$633K	Hold	11,900	–	–	0.02%	88
2022 Q2	$694K	Buy	11,900 +3,300	+38%	+$216K	0.02%	85
2022 Q1	$656K	Hold	8,600	–	–	0.02%	91
2021 Q4	$517K	Buy	+8,600	New	+$474K	0.02%	95

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Polaris Capital Management's PCRX Position: Q3 2024 in Review

Polaris Capital Management sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 5,600 shares — an estimated $160K sold.

Polaris Capital Management first reported a position in PCRX in Q4 2021 and held it in 11 quarters. The position peaked at $1.03M in Q1 2023. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

Polaris Capital Management reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
Polaris Capital Management sold 5,600 Pacira BioSciences shares in Q3 2024, an estimated $160K.
Polaris Capital Management first reported a position in Pacira BioSciences in Q4 2021 and held it in 11 quarters.
Polaris Capital Management's Pacira BioSciences position peaked at $1.03M in Q1 2023.
239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on Polaris Capital Management's 13F filing for Q3 2024, filed 13 Nov 2024.